title: Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
abstract: BACKGROUND
  In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant.
  
  
  METHODS
  Pre-transplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin inhibitor-based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven acute rejection (AR) episodes within first six months of the transplant. Post-transplant sera of patients with AR were tested for the presence of donor-specific HLA antibodies (DSA).
  
  
  RESULTS
  Overall AR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared with those patients negative for both the tests (36% vs. 5%, p=0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% vs. 5%, p=0.04). Of the 18 patients with AR, 14 were positive for sCD30, and 13 of them (93%) developed DSA post-transplant (p=0.001).
  
  
  CONCLUSIONS
  These data showed that patients positive for sCD30 contents are at high risk for the development of DSA and AR post-transplant regardless of their pre-transplant PRA.
authors.affiliation: Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0178, USA. svaidya@utmb.edu
authors.forename: Smita
authors.initials: S
authors.lastname: Vaidya
authors.forename: David
authors.initials: D
authors.lastname: Partlow
authors.forename: Titus
authors.initials: T
authors.lastname: Barnes
authors.forename: Phillip
authors.initials: P
authors.lastname: Thomas
authors.forename: Kristin
authors.initials: K
authors.lastname: Gugliuzza
mesh_terms: D015703:Antigens, CD / Q000097:blood; D001402:B-Lymphocytes / Q000276:immunology; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D017730:Ki-1 Antigen / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D012086:Reoperation; D012189:Retrospective Studies; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; D006680:HLA Antigens; D007518:Isoantibodies; D017730:Ki-1 Antigen